New combo before liver surgery aims to stop cancer return
NCT ID NCT07239245
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining a liver-directed procedure (TACE) with two drugs—atezolizumab (immunotherapy) and bevacizumab (anti-angiogenic)—given before surgery can improve outcomes for patients with liver cancer at high risk of recurrence. About 30 adults with resectable hepatocellular carcinoma and high-risk features will receive the combination, then undergo surgery. The main goal is to see how many patients have no remaining cancer cells in the removed tumor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab and bevacizumab (immunotherapy and anti-angiogenic drugs) plus transarterial chemoembolization (TACE) procedure
What this could lead to
If successful, this combination could become a standard neoadjuvant treatment to shrink liver tumors before surgery and lower the chance of cancer coming back.
What could go wrong
This is a small, early-phase trial with only 30 participants and no comparison group. The added drugs may cause side effects like bleeding or immune reactions, and the benefit over standard care is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Science
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
NOT_YET_RECRUITINGZhengzhou, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Cancer Hospital
NOT_YET_RECRUITINGTaiyuan, Shanxi, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Hospital of China Medical University
NOT_YET_RECRUITINGShenyang, Liaoning, China
Contact Phone: •••-•••-•••• Email: •••••@•••••